Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048772541> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2048772541 endingPage "2408" @default.
- W2048772541 startingPage "2406" @default.
- W2048772541 abstract "The aim of the study was to define the maximum tolerated dose (MTD) of vinorelbine given as one or two weekly doses in combination with epirubicin 60 mg/m2 every third week. The MTD was defined as the dose resulting in a WHO grade III or IV leucopenia exceeding 50% of patients. Patients were treated in groups of 10 at escalating doses of vinorelbine. The number of patients at the final dose level was expanded to 20. The dose of epirubicin was kept constant at 60 mg/m2 every third week. At dose level 1, 15 mg/m2 vinorelbine was given on day 1 at level 2, 20 mg/m2 was given on day 1 and at level 3, 20 mg/m2 was given on days 1 and 8. The MTD was reached at dose level 3. WHO haematological toxicity grade IV occurred in 0, 10 and 45% and grade III at 60, 30 and 30% of patients at dose levels 1, 2 and 3, respectively. Despite the common occurrence of grade IV haematological toxicity, only two serious infections were noted. Non-haematological toxicity of vinorelbine included neurotoxicity, manifesting as muscle weakness, constipation and paresthesias in the majority of patients. Neurotoxicity was usually mild and did not require treatment discontinuation. Phlebitis at the injection site was troublesome in many patients. Alopecia and nausea, probably due to epirubicin, occurred in most patients. The response rates were 22% (95% CI (confidence interval) 3-60%), 40% (12-74%) and 60% (36-81%) at levels 1, 2 and 3, respectively (non-significant)." @default.
- W2048772541 created "2016-06-24" @default.
- W2048772541 creator A5031397515 @default.
- W2048772541 creator A5044392768 @default.
- W2048772541 creator A5057232593 @default.
- W2048772541 creator A5062149739 @default.
- W2048772541 date "1995-12-01" @default.
- W2048772541 modified "2023-09-24" @default.
- W2048772541 title "Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study" @default.
- W2048772541 cites W1843618725 @default.
- W2048772541 cites W1978526423 @default.
- W2048772541 cites W2029856305 @default.
- W2048772541 cites W2064367468 @default.
- W2048772541 cites W2083418878 @default.
- W2048772541 cites W2172570236 @default.
- W2048772541 cites W2271753451 @default.
- W2048772541 cites W2285207413 @default.
- W2048772541 doi "https://doi.org/10.1016/0959-8049(95)00416-5" @default.
- W2048772541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8652277" @default.
- W2048772541 hasPublicationYear "1995" @default.
- W2048772541 type Work @default.
- W2048772541 sameAs 2048772541 @default.
- W2048772541 citedByCount "17" @default.
- W2048772541 countsByYear W20487725412020 @default.
- W2048772541 crossrefType "journal-article" @default.
- W2048772541 hasAuthorship W2048772541A5031397515 @default.
- W2048772541 hasAuthorship W2048772541A5044392768 @default.
- W2048772541 hasAuthorship W2048772541A5057232593 @default.
- W2048772541 hasAuthorship W2048772541A5062149739 @default.
- W2048772541 hasConcept C121608353 @default.
- W2048772541 hasConcept C126322002 @default.
- W2048772541 hasConcept C141071460 @default.
- W2048772541 hasConcept C2776694085 @default.
- W2048772541 hasConcept C2778239845 @default.
- W2048772541 hasConcept C2778715236 @default.
- W2048772541 hasConcept C2779491297 @default.
- W2048772541 hasConcept C2780350996 @default.
- W2048772541 hasConcept C2780580376 @default.
- W2048772541 hasConcept C2780835546 @default.
- W2048772541 hasConcept C29730261 @default.
- W2048772541 hasConcept C530470458 @default.
- W2048772541 hasConcept C71924100 @default.
- W2048772541 hasConcept C90924648 @default.
- W2048772541 hasConceptScore W2048772541C121608353 @default.
- W2048772541 hasConceptScore W2048772541C126322002 @default.
- W2048772541 hasConceptScore W2048772541C141071460 @default.
- W2048772541 hasConceptScore W2048772541C2776694085 @default.
- W2048772541 hasConceptScore W2048772541C2778239845 @default.
- W2048772541 hasConceptScore W2048772541C2778715236 @default.
- W2048772541 hasConceptScore W2048772541C2779491297 @default.
- W2048772541 hasConceptScore W2048772541C2780350996 @default.
- W2048772541 hasConceptScore W2048772541C2780580376 @default.
- W2048772541 hasConceptScore W2048772541C2780835546 @default.
- W2048772541 hasConceptScore W2048772541C29730261 @default.
- W2048772541 hasConceptScore W2048772541C530470458 @default.
- W2048772541 hasConceptScore W2048772541C71924100 @default.
- W2048772541 hasConceptScore W2048772541C90924648 @default.
- W2048772541 hasIssue "13-14" @default.
- W2048772541 hasLocation W20487725411 @default.
- W2048772541 hasLocation W20487725412 @default.
- W2048772541 hasOpenAccess W2048772541 @default.
- W2048772541 hasPrimaryLocation W20487725411 @default.
- W2048772541 hasRelatedWork W1999410266 @default.
- W2048772541 hasRelatedWork W2070887197 @default.
- W2048772541 hasRelatedWork W2357863562 @default.
- W2048772541 hasRelatedWork W2375393782 @default.
- W2048772541 hasRelatedWork W2376759146 @default.
- W2048772541 hasRelatedWork W2385117354 @default.
- W2048772541 hasRelatedWork W2411038342 @default.
- W2048772541 hasRelatedWork W2596366279 @default.
- W2048772541 hasRelatedWork W2897258609 @default.
- W2048772541 hasRelatedWork W3032564633 @default.
- W2048772541 hasVolume "31" @default.
- W2048772541 isParatext "false" @default.
- W2048772541 isRetracted "false" @default.
- W2048772541 magId "2048772541" @default.
- W2048772541 workType "article" @default.